New Members

The TBDA welcomed two new members after the October 2021 semi-annual meeting. 

Professor Radojka M. Savic, University of California, San Francisco

The team specializes in data-driven pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation as a resource for improving global health. They apply quantitative, model-based principles of drug response and disease dynamics to optimize doses, dosing schedules, drug regimens and treatment durations, potentially bringing novel therapies to patients with unmet needs

Bill & Melinda Gates Medical Research Institute

The team specializes in evaluating novel biomarkers of drug and drug regimen effect both pre-clinically and clinically, working with collaborators to improve and develop existing and newer animal models, evaluating drug candidates and targets to enhance treatment shortening for TB, and providing expertise and a potential development pathway for TBDA members’ drug candidates.